DRUG

cabozantinib

3 hypotheses across 2 therapeutic domains

ALL HYPOTHESES

Repurposing candidates for cabozantinib

Inflammatory bowel disease 1

Mediator Outcome Score Tier Lit. status Trial
AXL IBD 0.208 Mid novel signal active

Rheumatoid arthritis 2

Mediator Outcome Score Tier Lit. status Trial
AXL low disease activity 0.208 Mid novel signal none
AXL pro-inflammatory gene expression 0.208 Mid novel signal none

Clinical trials

200 registered trials for cabozantinib

Source: ClinicalTrials.gov